Merck & Co Inc MRK is scheduled to report its first-quarter earnings on Thursday before the market opens. Analysts on Wall Street anticipate earnings per share of $2.14 alongside expected revenue of $15.33 billion.

Over the past year, Merck’s stock has faced significant challenges, declining 38.04%. Year-to-date, it has dropped 20.73%, with a 14.85% decline in just the past month. This positions Merck among the hardest-hit companies within the Big Pharma sector.

This article examines the current trends for Merck stock and how these compare to Wall Street’s projections.

Read also: Gilead Cancer Drug Combined With Merck’s Drug Effective In Difficult To Treat Type Of Breast Cancer

Chart created using Benzinga Pro

From a technical standpoint, Merck stock shows a bearish trend; however, there are hints of possible recovery. Currently trading well below its five-, 20-, and 50-day exponential moving averages, the stock signals a strong bearish trend. Nevertheless, an undercurrent of buying pressure could indicate a potential bullish reversal, especially if earnings exceed expectations.

At $78.56, Merck’s stock price slightly exceeds its eight-day simple moving average (SMA) of $78.32, suggesting short-term bullish momentum. However, the outlook remains bleak when considering the 20-day SMA of $82.12 and the 50-day SMA of $87.48, both indicating continued bearish pressure.

The 200-day SMA stands at a formidable $102.90, further illuminating the stock’s struggles in the current market environment.

Momentum indicators reflect this sentiment: the MACD (moving average convergence/divergence) is negative at -3.36, while the RSI (relative strength index) is at 36.36, nearing oversold territory. This indicates the bearish sentiment remains strong unless bulls capitalize on a robust earnings report.

Ratings & Consensus Estimates: Despite the downturn, analysts maintain a sense of cautious optimism. Merck retains a Buy consensus rating, with a mean price target estimated at $121. Recent ratings from firms including Cantor Fitzgerald, Guggenheim, and Deutsche Bank average a target of $101.67. This suggests a potential upside of 29.41% from current prices.

MRK Stock Price Action: At the time of publication Wednesday, Merck stock was trading at $78.68, down 0.37%.

Read Next:

Photo: Shutterstock